Io Biotech Aps has presented preclinical data regarding their Arg1-derived peptide cancer vaccine IO-112 as a potential immunotherapeutic that would allow controlling the tumor microenvironment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback